Strong Overall Revenue and Profit Growth
Net (adjusted) revenues of $470M in Q1 2026, up 22% year-over-year; operating income of $94M and operating margin of 20%; net income $72M and diluted adjusted EPS of $1. This was the tenth consecutive quarter of year-over-year revenue growth.
Record Corporate Investment Banking Performance
Corporate Investment Banking revenues of $324M, a first-quarter record and up 30% year-over-year, driven by robust corporate financing activity and advisory contributions.
Advisory Revenues at an All-Time High
Advisory revenues were a first-quarter record of $251M, up 16% year-over-year. Firm ranked #1 adviser in U.S. bank M&A by deal value (quarter), #2 in U.S. M&A by announced deals under $2B, and #3 under $5B; #1 adviser in U.S. medtech M&A by announced deals.
Corporate Financing and Equity Underwriting Surge
Corporate Financing revenues of $73M, up 122% year-over-year; equity underwriting fee pool up 73% year-over-year. Completed 36 equity, debt and preferred financings raising $14B for clients, with Healthcare leading issuance.
Strong Brokerage and Trading Results
Equity Brokerage delivered record Q1 revenues of $60M, up 11% year-over-year driven by higher volatility and increased hedging activity; Fixed Income revenues of $50M, up 6% year-over-year (despite late-quarter volatility).
Margin Expansion and Cost Discipline
Operating income grew 37% year-over-year, outpacing revenue growth (22%). Compensation ratio improved to 61.6% (90 bps improvement year-over-year). Non-compensation expenses (ex-litigation) increased 4% y/y and were 16.6% of net revenues, a 300 bps improvement.
Capital Return and Shareholder Actions
Returned $171M to shareholders in Q1 (dividends $101M / $1.45 per share including special dividend; share repurchases ~$70M for ~884k shares). Board approved a quarterly dividend of $0.20 per share, a 14% increase. Completed a 4-for-1 forward stock split.
Talent and Platform Expansion
Reached 192 investment banking Managing Directors (firm high); promoted 6 bankers and hired 3 MDs to strengthen Healthcare, IT, European Life Sciences and Upstream Energy capabilities. Private Capital Advisory and Debt Capital Markets Advisory showing positive momentum.